Valuation: Evofem Biosciences, Inc.

Market Cap 997K 861K 809K 736K 1.38M 95.35M 1.41M 9.48M 3.71M 47.75M 3.74M 3.66M 159M P/E 2024
-0.08x
P/E 2025 26.7x
Enterprise Value 55.41M 47.86M 44.97M 40.9M 76.9M 5.3B 78.17M 527M 206M 2.65B 208M 204M 8.82B EV / Sales 2024
2.43x
EV / Sales 2025 2.76x
Free-Float
100%
Yield 2024 *
-
Yield 2025 -
1 day+7.59%
1 week+6.25%
Current month+21.43%
1 month+6.25%
3 months+26.87%
6 months-2.30%
Current year-10.53%
1 week 0.01
Extreme 0.0065
0.01
1 month 0.01
Extreme 0.0065
0.01
Current year 0
Extreme 0.0008
0.01
1 year 0
Extreme 0.0008
0.02
3 years 0
Extreme 0.0008
0.27
5 years 0
Extreme 0.0008
1,826.62
10 years 0
Extreme 0.0008
23,549.99
Manager TitleAgeSince
Chief Executive Officer 57 01/01/2018
Director of Finance/CFO 49 13/04/2023
Chief Operating Officer - -
Director TitleAgeSince
Chairman 57 -
Director/Board Member 67 01/01/2018
Director/Board Member 58 01/01/2018
Date Insider Type Main position Quantity % Market Cap.
12/1/24 Sell

Chief Financial Officer

104 0.0010%
21/12/23 Sell

Director

10 0.0001%
13/4/23 Other

Chief Financial Officer

13,000 0.0107%
Change 5-day change 1-year change 3-year change Capi.($)
+7.59%+6.25%-9.57%-97.34% 997K
-2.25%-0.47%+68.30%+115.90% 1,052B
-0.66%+0.43%+47.39%+50.54% 627B
-0.54%+1.39%+20.69%+63.99% 441B
-1.99%-3.32%+38.71%+35.41% 349B
-1.05%-2.81%+23.07%+35.70% 287B
-2.12%-3.67%-1.14%+5.37% 241B
-0.63%+1.04%+40.05%+56.09% 224B
-1.19%-3.41%-9.57%-52.71% 202B
+0.16%+3.87%+16.89%+73.73% 172B
Average -0.27%+0.39%+23.48%+28.67% 359.52B
Weighted average by Cap. -1.36%+0.32%+39.09%+61.29%

Financials

2024 2025
Net sales 19.36M 16.72M 15.72M 14.29M 26.87M 1.85B 27.31M 184M 72M 927M 72.7M 71.12M 3.08B 20.18M 17.43M 16.38M 14.9M 28.01M 1.93B 28.47M 192M 75.04M 966M 75.78M 74.13M 3.21B
Net income -8.86M -7.65M -7.19M -6.54M -12.3M -847M -12.5M -84.26M -32.94M -424M -33.26M -32.54M -1.41B 391K 338K 317K 289K 543K 37.39M 552K 3.72M 1.45M 18.72M 1.47M 1.44M 62.22M
Net Debt 45.84M 39.59M 37.2M 33.84M 63.61M 4.38B 64.66M 436M 170M 2.2B 172M 168M 7.29B 54.42M 47M 44.17M 40.17M 75.52M 5.2B 76.76M 517M 202M 2.61B 204M 200M 8.66B
Logo Evofem Biosciences, Inc.
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is commercializing its products to address unmet needs in women’s sexual and reproductive health. The Company’s first approved product, PHEXXI (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of over 12 pre-filled applicators and is applied 0-60 minutes before each act of intercourse. PHEXXI is a gel that works to prevent pregnancy without the use of hormones. PHEXXI prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Using the PHEXXI telehealth platform, women can directly meet with a health care provider to determine their eligibility for a PHEXXI prescription. The Company also commercialized SOLOSEC (secnidazole) 2g oral granules, an antibiotic for the treatment of two sexual health diseases such as bacterial vaginosis and trichomoniasis.
Employees
29
Date Price Change Volume
14/08/26 USD 0.007524 -4.15% 103,320
13/08/26 USD 0.007850 +9.03% 344,236
12/08/26 USD 0.007200 -12.20% 216,008
11/08/26 USD 0.008200 +13.89% 198,219
10/08/26 USD 0.007200 -10.00% 197,062

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EVFM Stock